Specialist Oversight for High-Complexity Oncology Research
UK Hospitals
Hospital Staff Relationships
Years of Experience
While our operational reach extends across various therapeutic areas, we possess a dedicated specialism in navigating the unique intricacies of cancer research. We work globally to provide both targeted phase-specific assistance and comprehensive end-to-end management for clinical trials.
We partner with biotechs, medtech firms, and academic or NHS sponsors to execute protocols that are scientifically rigorous, logistically viable, and designed with a deep understanding of the patient experience.
Our portfolio is particularly strong in the management of both solid tumours and haematological malignancies. We understand that blood-based cancers require a distinct approach to trial design, often involving complex cellular therapies or intensive monitoring of bone marrow and blood markers.
This dual expertise allows us to support a broad oncological portfolio while addressing the specific clinical nuances of each disease type.
Navigating the Nuances of
Oncology Studies
Clinical trials in this field are the primary engine for advancements in the prevention, detection, and treatment of disease.
These protocols often involve high-risk interventions, requiring vigilant safety oversight and the monitoring of sophisticated endpoints such as progression-free survival or minimal residual disease.
Given that participants may be acutely unwell or have undergone extensive prior therapies, study designs must carefully balance scientific ambition with what is practically safe and feasible.
The Necessity of Niche Expertise in Diverse Indications
Cancer is rarely a uniform disease; even a single indication can involve a multitude of molecular profiles and varying treatment histories.
This heterogeneity influences every facet of a trial, from the precision of recruitment criteria to the complexity of the statistical model.
In early-phase research, sponsors must generate high-quality safety data while exploring novel combinations or targeted therapies within small, meticulously monitored cohorts.
These trials are conducted in high-pressure environments. Integrating procedures like bone marrow aspirations, complex imaging, and intensive laboratory monitoring into existing patient care pathways requires a partner who understands how to avoid site fatigue while maintaining data integrity.
A Proven Track Record in Complex Clinical Delivery
We have established a robust history of managing early-phase and complex studies, including first-in-human and first-in-patient trials.
Our experience spans a wide range of indications, including myeloma, lymphoma, myelodysplastic syndrome, and mixed solid tumours bridging the gap between pioneering laboratory science and the practicalities of the UK’s research infrastructure.
Our work often involves close coordination with investigators and specialist networks, such as the Experimental Cancer Medicine Centre (ECMC), to deliver intensive data collection and stringent safety management.
A Collaborative Model for Trial Management
Sponsors choose us when they require a specialist team that functions as a seamless extension of their own organisation.
Our boutique structure ensures direct access to senior leadership and the continuity of a dedicated project team from the planning stages through to close-out.
This stability is vital in oncology, where protocols must often pivot quickly in response to emerging safety data or shifts in the standard clinical landscape.
Case Study: Executing a Phase I Study for Relapsed Glioblastoma
We managed the site operations for the CITADEL-123 trial, a first-in-human study evaluating \({}^{123}\)I-ATT001 in patients with relapsed glioblastoma.
This programme was operationally demanding, requiring the precise synchronisation of therapeutic payload production with clinical administration via Ommaya reservoirs at high-speciality neuro-oncology sites [
1, 2, 3]
The primary challenge lay in the indication; glioblastoma is an exceptionally difficult patient population to reach, and finding suitable sites with the niche combination of surgical infrastructure and therapeutic licensure was a significant barrier.
We triumphed by leveraging our deep industry intelligence to pinpoint and activate the rare centres capable of managing direct intracranial delivery.
Our team directed the rollout, specifically overcoming the regulatory hurdles associated with the transport and handling of the investigational agent.
Our senior-led oversight ensured that the high-frequency dosimetry measurements and vigilant safety tracking required for this PARP-inhibitor-targeted therapy were performed with absolute accuracy. This provided the sponsor with a clean and robust data set to support their early-phase milestones.